• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    3/8/21 5:19:17 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $XTNT alert in real time by email
    SC 13G 1 xtnt-sc13g_022421.htm ACQUISITION OF BENEFICIAL OWNERSHIP

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

    Xtant Medical Holdings, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.000001 per share

    (Title of Class of Securities)

     

     

    98420P308

    (CUSIP Number)

     

    February 24, 2021
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

      ☐ Rule 13d-1(b)
         
      ☒ Rule 13d-1(c)
         
      ☐ Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

       
      Page 2 of 8

     

    CUSIP No.    98420P308

     

    1

    NAME OF REPORTING PERSONS
    Altium Capital Management, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2066653

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    8,663,889 shares of Common Stock

    6,497,917 shares of Common Stock issuable upon exercise of Warrants (1)

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    8,663,889 shares of Common Stock

    6,497,917 shares of Common Stock issuable upon exercise of Warrants (1)

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    8,663,889 shares of Common Stock

    6,497,917 shares of Common Stock issuable upon exercise of Warrants (1)

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.99% (2)

     
    12

    TYPE OF REPORTING PERSON

    IA, PN

     
             

    ____________

    (1)    Based on 86,707,286 shares, which is the aggregate of 77,818,396 shares of Common Stock outstanding as set forth in the Issuer’s 10-K dated February 22, 2021 filed with the Securities and Exchange Commission (the “Commission”) on February 26, 2021 and 8,888,890 shares to be issued as disclosed in the Issuer’s 8-K dated February 22, 2021 filed with the Commission on February 22, 2021.

     

    (2)    As more fully described in Item 4, the Warrants are subject to a 9.99% blocker. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by each such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

     

       
      Page 3 of 8

     

    CUSIP No. 98420P308    

     

    1

    NAME OF REPORTING PERSONS
    Altium Growth Fund, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2105101

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    8,663,889 shares of Common Stock

    6,497,917 shares of Common Stock issuable upon exercise of Warrants (1)

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    8,663,889 shares of Common Stock

    6,497,917 shares of Common Stock issuable upon exercise of Warrants (1)

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    8,663,889 shares of Common Stock

    6,497,917 shares of Common Stock issuable upon exercise of Warrants (1)

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.99% (2)

     
    12

    TYPE OF REPORTING PERSON

    PN

     
             

    ____________

    (1)    Based on 86,707,286 shares, which is the aggregate of 77,818,396 shares of Common Stock outstanding as set forth in the Issuer’s 10-K dated February 22, 2021 filed with the Securities and Exchange Commission (the “Commission”) on February 26, 2021 and 8,888,890 shares to be issued as disclosed in the Issuer’s 8-K dated February 22, 2021 filed with the Commission on February 22, 2021.

     

    (2)    As more fully described in Item 4, the Warrants are subject to a 9.99% blocker. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by each such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9). 

     

     

       
      Page 4 of 8

     

    CUSIP No. 98420P308    

     

    1

    NAME OF REPORTING PERSONS

    Altium Growth GP, LLC

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2086430

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    8,663,889 shares of Common Stock

    6,497,917 shares of Common Stock issuable upon exercise of Warrants (1)

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    8,663,889 shares of Common Stock

    6,497,917 shares of Common Stock issuable upon exercise of Warrants (1)

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    8,663,889 shares of Common Stock

    6,497,917 shares of Common Stock issuable upon exercise of Warrants (1)

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.99% (2)

     
    12

    TYPE OF REPORTING PERSON

    OO

     
             

    ____________

    (1)    Based on 86,707,286 shares, which is the aggregate of 77,818,396 shares of Common Stock outstanding as set forth in the Issuer’s 10-K dated February 22, 2021 filed with the Securities and Exchange Commission (the “Commission”) on February 26, 2021 and 8,888,890 shares to be issued as disclosed in the Issuer’s 8-K dated February 22, 2021 filed with the Commission on February 22, 2021.

     

    (2)    As more fully described in Item 4, the Warrants are subject to a 9.99% blocker. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by each such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

     

       
      Page 5 of 8

     

     

    CUSIP No.   98420P308    

     

    Item 1(a). Name of Issuer:                                                          Xtant Medical Holdings, Inc. (the “Issuer”)
       

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:  

    664 Cruiser Lane

    Belgrade, Montana 59714

     

    Item 2(a).

    Name of Person Filing:

    This statement is jointly filed by and on behalf of each of Altium Growth Fund, LP (the “Fund”), Altium Capital Management, LLC, and Altium Growth GP, LLC. The Fund is the record and direct beneficial owner of the securities covered by this statement. Altium Capital Management, LP is the investment adviser of, and may be deemed to beneficially own securities, owned by, the Fund. Altium Growth GP, LLC is the general partner of, and may be deemed to beneficially own securities owned by, the Fund.

     

    Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

     

    Each of the reporting persons may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the reporting persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

       
    Item 2(b). Address of Principal Business Office or, if None, Residence:
      The address of the principal business office of each of the reporting persons is
    152 West 57th Street, FL 20, New York, NY 10019
       
    Item 2(c). Citizenship:
      See Item 4 on the cover page(s) hereto.
       
    Item 2(d). Title of Class of Securities:
      Common Stock, par value 0.000001 per share (“Common Stock”)
       
    Item 2(e). CUSIP Number: 98420P308
       

     

    Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:
       
      (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

     

     

       
      Page 6 of 8

     

    CUSIP No. 98420P308    

     

      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G);
           
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).
           

     

    Item 4. Ownership.

     

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person listed above and is incorporated by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 86,707,286 shares, which is the aggregate of 77,818,396 shares of Common Stock outstanding as set forth in the Issuer’s 10-K dated February 22, 2021 filed with the Securities and Exchange Commission (the “Commission”) on February 26, 2021 and 8,888,890 shares to be issued as disclosed in the Issuer’s 8-K dated February 22, 2021 filed with the Commission on February 22, 2021.

     

    Pursuant to the terms of the securities purchase agreement entered into between the Fund and the Issuer, the Fund purchased Common Stock and Warrants. The Reporting Persons cannot exercise the Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 9.99% of the outstanding shares of Common Stock (the “Warrant Blocker”). The percentage set forth in Row 11 of the cover page for each Reporting Person gives effect to the Warrant Blocker.

     

       
      Page 7 of 8

     

    CUSIP No .   98420P308    

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☐
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
      Not applicable
       
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable
       
       
    Item 8. Identification and Classification of Members of the Group.
      Not applicable
       
       
    Item 9. Notice of Dissolution of Group.
      Not applicable
       
    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

      Dated: March 8, 2021  
         
      Altium Capital Management, LP  
         
      By: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb  
      Title: CEO  
         
     

    Altium Growth Fund, LP

     

    By: Altium Growth GP, LLC

    Its: General Partner

     

     
      Signature: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb  
      Title: Managing Member of Altium Growth GP, LLC  
           
      Altium Growth GP, LLC  
         
      By: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb  
      Title: Managing Member  

     

     

     

       
      Page 8 of 8

     

    EXHIBIT INDEX

     

     

    EXHIBIT 1: Joint Acquisition Statement Pursuant to Section 240.13d-1(k)
       
      Members of Group

     

     

     

     

       

     

    Get the next $XTNT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XTNT

    DatePrice TargetRatingAnalyst
    12/5/2023$2.00Buy
    BTIG Research
    More analyst ratings

    $XTNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Nantahala Capital Management, Llc claimed ownership of 68,394,000 shares (SEC Form 3)

      3 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

      4/17/25 4:31:14 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Orbimed Advisors Llc sold $30,708,129 worth of shares (73,114,592 units at $0.42) (SEC Form 4)

      4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

      4/14/25 7:14:36 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: Chief Operations Officer Schallenberger Mark A. was granted 173,469 shares, increasing direct ownership by 85% to 378,613 units (SEC Form 4)

      4/A - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

      1/17/25 4:29:24 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $XTNT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Xtant Medical to Issue First Quarter 2025 Financial Results on May 12, 2025

      BELGRADE, Mont., May 6, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and woundcare disorders, today announced that it will release its financial results for the first quarter ended March 31, 2025, after the close of the financial markets on Monday, May 12, 2025. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Monday, May 12, 2025 at 4:30 PM ET to review results. Conference Details:Conference Date: Monday, May 12, 2025Conference Time: 4:30 PM ETConference dial-in: 888-506-0062International dial

      5/6/25 8:00:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical Launches Trivium™ Advanced Bone Graft for Superior Performance

      BELGRADE, Mont., April 23, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc.(NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and woundcare disorders, is proud to announce the launch of Trivium™, a premium, next-generation demineralized bone matrix (DBM) allograft designed to elevate the standard of care in bone grafting procedures. Engineered with advanced PureLoc™ Fiber Technology, Trivium combines three synergistic elements intended to deliver exceptional performance in structure, handling, and biological activity.

      4/23/25 8:00:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical Announces Secondary Private Sale of Existing Shares by OrbiMed and Preliminary First Quarter 2025 Revenue Growth of 18% to 19%

      Healthcare Focused Long-term Investors Support Strategic Vision Accelerating Shift to Higher-Margin Orthobiologics Supported by New Product Launches BELGRADE, Mont., April 16, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and woundcare disorders, today announced the completion of a secondary private sale of 73.1 million shares of Xtant common stock held by funds affiliated with OrbiMed Advisors LLC ("OrbiMed") to several existing and new stockholders, led by Nantahala Capital Management LLC ("Nantahala"). Sean Browne, President and CEO of Xtant Medical, stated, "We want

      4/16/25 8:05:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $XTNT
    SEC Filings

    See more
    • Xtant Medical Holdings Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Results of Operations and Financial Condition, Changes in Control of Registrant, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)

      4/16/25 4:55:59 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Xtant Medical Holdings Inc.

      SCHEDULE 13G - Xtant Medical Holdings, Inc. (0001453593) (Subject)

      4/16/25 2:11:44 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Xtant Medical Holdings Inc.

      SCHEDULE 13D/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)

      4/14/25 7:09:38 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $XTNT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $XTNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Brandt Kevin D bought $49,837 worth of shares (41,670 units at $1.20), increasing direct ownership by 5% to 815,860 units (SEC Form 4)

      4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

      11/17/23 4:42:41 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BTIG Research initiated coverage on Xtant Medical with a new price target

      BTIG Research initiated coverage of Xtant Medical with a rating of Buy and set a new price target of $2.00

      12/5/23 8:12:02 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $XTNT
    Leadership Updates

    Live Leadership Updates

    See more
    • Apyx Medical Corporation Announces Board Leadership Transition

      Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead

      5/9/24 7:00:00 AM ET
      $APYX
      $BVS
      $XTNT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Xtant Medical Appoints Lori Mitchell-Keller to Board of Directors

      BELGRADE, Mont., May 18, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Lori Mitchell-Keller to the Company's Board of Directors effective May 16, 2023. Ms. Mitchell-Keller will serve as a member of the Compensation and Audit Committees of the Board of Directors. "We are pleased to welcome Lori to our Board, marking another high-quality independent member addition," said Stavros G. Vizirgianakis, Chairman of Xtant's Board of Directors. "Her deep operations, information technologies, and marketing expertise will be of significant va

      5/18/23 8:00:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical Appoints Mark Schallenberger as Chief Operations Officer

      BELGRADE, Mont., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Mark Schallenberger as Chief Operations Officer, effective January 16, 2023. "We are thrilled to have Mark rejoin the team as we reinvent Xtant," said Sean Browne, President and Chief Executive Officer of Xtant Medical. "In this newly created role, Mark will drive the modernization of our production, lead the optimization of our processes and operations, and support the diversification and development of new product lines. We look forward to Mark's contributio

      1/9/23 8:00:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $XTNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Xtant Medical Holdings Inc.

      SC 13D/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)

      9/10/24 4:12:57 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Xtant Medical Holdings Inc. (Amendment)

      SC 13G/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)

      2/13/24 5:10:19 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Xtant Medical Holdings Inc. (Amendment)

      SC 13D/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)

      8/3/23 4:59:55 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $XTNT
    Financials

    Live finance-specific insights

    See more
    • Xtant Medical to Issue First Quarter 2025 Financial Results on May 12, 2025

      BELGRADE, Mont., May 6, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and woundcare disorders, today announced that it will release its financial results for the first quarter ended March 31, 2025, after the close of the financial markets on Monday, May 12, 2025. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Monday, May 12, 2025 at 4:30 PM ET to review results. Conference Details:Conference Date: Monday, May 12, 2025Conference Time: 4:30 PM ETConference dial-in: 888-506-0062International dial

      5/6/25 8:00:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical Reports Third Quarter 2024 Financial Results

      Third Quarter Revenue Growth of 12%Reaffirms Full Year 2024 Revenue Guidance of $116 Million to $120 MillionRepresenting Growth of 27% to 31% BELGRADE, MT / ACCESSWIRE / November 12, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2024.Third Quarter 2024 Financial HighlightsRevenue of $27.9 million, up 12%, compared to the prior year quarter; year to date revenue of $85.8 million, up 36% compared to prior year periodGross margin of 58.4% compared to 61.3% for the prior year quarterNet loss of $5.0 mi

      11/12/24 4:05:00 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical to Issue Third Quarter 2024 Financial Results on November 12, 2024

      BELGRADE, MT / ACCESSWIRE / November 7, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the third quarter ended September 30, 2024, after the close of the financial markets on Tuesday, November 12, 2024.Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Tuesday, November 12, 2024 at 4:30 PM ET to review results.Conference Details:Conference Date: Tuesday, November 12, 2024Conference Time: 4:30 PM ETConference dial-in: 888-999-3182International dial-in:

      11/7/24 10:45:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care